17.05.2018
Vita 34 AG DE000A0BL849
DGAP-News: Vita 34 introduces entry-level pricing model 'VitaPur' and implements first cost reduction measures
DGAP-News: Vita 34 AG / Key word(s): Product Launch/Regulatory Approval
Vita 34 introduces entry-level pricing model 'VitaPur' and implements first
cost reduction measures
17.05.2018 / 07:28
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Vita 34 introduces entry-level pricing model "VitaPur" and implements first
cost reduction measures
- New pricing model "VitaPur" for the development of price-sensitive market
segment
- DFB goalkeeping coach Andreas Köpke becomes patron of Vita 34 fundraising
week for official product launch
- Approval of Paul Ehrlich Institute to extend duration of logistics process
as first part of cost reduction program
Leipzig, 17 May 2018 - Vita 34 AG (ISIN: DE000A0BL849, WKN: A0BL84), the
second largest stem cell bank in Europe, will present its new pricing model
"VitaPur" on the market tomorrow. The new product addresses price-sensitive
customers with a new pricing structure and should help to systematically
increase market penetration in the core markets of the DACH region.
Compared to the classic pricing models "VitaPlus" and "VitaPlusNabelschnur",
"VitaPur" is characterized by a significantly reduced upfront payment for
the storage of umbilical cord blood. In return, the regularly recurring
annual fees of this pricing model are higher. Specifically, the fees in the
pricing model "VitaPur" consist of a one-time payment of 990.00 euros and an
annual fee of 120.00 euros amount. "VitaPur" will exclusively include the
storage of umbilical cord blood. In order to increase the number of publicly
available preparations and thus the number of applications, tissue typing
and entry in a public stem cell registry is obligatory, as with
"VitaPlusSpende", if suitably qualified. "On the one hand, VitaPur is very
attractive to the customer due to the lower upfront payment, and on the
other hand, the economic value for Vita 34 is even higher all things
considered than in our classic pricing structures. We therefore expect that
any cannibalization effects will at least be compensated by spill-over
effects," explains Dr. Wolfgang Knirsch, CEO of Vita 34. "By registering in
our donations register, we want to strengthen public perception of the
chances of storing umbilical cord blood."
Therefore, the company launches the first Vita 34 donation campaign week for
the product launch. Expectant parents in Berlin will be able to register for
an umbilical cord blood donation by calling Vita 34 from 22 to 25 May.
Subsequently, these preparations are then analyzed in the laboratories of
Vita 34, processed and stored in the cryo-tanks of the company. From then on
they will be available to the public as a potentially life-saving donation.
As a patron of the donation campaign, Vita 34 was able to win Andreas Köpke,
goalkeeping coach of the German national football team. The campaign is also
supported by Berlin-based radio station "Spree Radio" as a media partner.
"More than 97 percent of the valuable stem cells from umbilical cord blood
still end up in hospital waste. The campaign is intended to help to make
chances of umbilical cord blood storage more visible to the general
population ", emphasizes Dr. med. Wolfgang Knirsch. "If successful, we want
to carry out this campaign in other cities as well in the future."
In addition, Vita 34's application for a prolongation of the maximum
permissible transport time of freshly drawn umbilical cord blood was
approved. The responsible Paul Ehrlich Institute, the Federal Institute for
Vaccines and Biomedical Drugs, has granted the approval to adapt the
existing manufacturing regulations after extensive review of all submitted
documentation and evidence. Thus, for Vita 34, the maximum permissible time
between collection and storage of umbilical cord blood increases from the
previous 48 hours to 72 hours in the future. If the previously valid 48-hour
limit was exceeded, the storage of a preparation was only possible after
additional examinations. Based on empirical documentation, Vita 34 has now
provided proof that the logistics method used by the company also keeps the
extracted blood in perfect condition for at least 72 hours.
"The granted approval allows us to structure our shipping and manufacturing
process more cost-effectively overall," explains Dr. Knirsch. "It's a first
step towards the sustainable cost savings we're aiming for as part of our
Vision 2021, and more will follow in the coming months. In addition, the
launch of VitaPur marks an important milestone in penetrating our markets in
the DACH region. This too is a central element of our vision 2021."
Against the backdrop of a conservative planning process and expected ramp-up
effects, the company's Executive Board expects only limited effects of the
aforementioned measures on revenues and earnings for the current financial
year. Therefore, the company is maintaining its current outlook for the
company's performance in the 2018 financial year unchanged.
Contact:
Ingo Middelmenne
Investor Relations
Vita 34 AG
Phone: +49 (0341) 48792 - 0
Mobile: +49 (0174) 9091190
Email: [email protected]
Company Profile
Vita 34 was founded in Leipzig in 1997 as the first private stem cell bank
in Europe and, as a complete provider of cryo-preservation services, offers
collection, logistics, preparation, and storage of stem cells from umbilical
cord blood and tissue. Stem cells are a valuable base material for medical
cell therapy and are kept alive at temperatures of minus 180 degrees
Celsius, in order to be available for use in a treatment if needed. More
than 200,000 customers from Germany and 28 other countries have already
provided for their children's future with a stem cell deposit at Vita 34.
---------------------------------------------------------------------------
17.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: [email protected]
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
686655 17.05.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Vita 34 AG ISIN: DE000A0BL849 können Sie bei EQS abrufen
Biotechnologie , A0BL84 , V3V , XETR:V3V